<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

Meet our speakers


Development of RNA therapeutics & vaccines

We're excited to announce the following speakers at RNA Leaders, with more to come.

Brett Monia, CEO, Ionis Pharmaceuticals

Brett Monia

CEO
Ionis Pharmaceuticals
Frank de Rosa, Chief Technology Officer & Global Head of Research, mRNA Center of Excellence, Sanofi

Frank de Rosa

CTO & Global Head of Research, mRNA Center of Excellence
Sanofi
Lucio Iannone, VP of Venture Investments Health, Leaps at Bayer

Lucio Iannone

VP of Venture Investments Health
Leaps at Bayer
Lovisa Afzelius, CEO, Alltrna, & Origination Partner, Flagship Pioneering

Lovisa Afzelius

CEO, Alltrna
Origination Partner, Flagship Pioneering
Peter Smith, CEO, Remix Therapeutics

Peter Smith

CEO
Remix Therapeutics
Matthew Disney, Chair, Scripps Research

Matt Disney

Professor, Department of Chemistry
Scripps Research
Dietrich Stephan

Dietrich Stephan

Chairman and Chief Executive Officer
NeuBase Therapeutics
Karen Chapman, CSO, Eclipsebio

Karen Chapman

CSO
Eclipsebio
Hans-Peter Vornlocher Managing Director Research Axolabs

Hans-Peter Vornlocher

Managing Director, Research
LGC Axolabs
Katarina Stenklo, Enterprise Solutions Commercial Activation Leader, Cytiva

Katarina Stenklo

Enterprise Solutions Commercial Activation Leader
Cytiva
Jeremy Little, Director, Custom Oligonucleotides, Chemgenes

Jeremy Little

Director, Custom Oligonucleotides
Chemgenes
Suzanne Saffie-Siebert CEO at SiSaf

Suzanne Saffie

CEO
SiSaf
David Oxley, President, Exopharm

David Oxley

President
Exopharm
Samuel Wickline, Chief Scientific Officer, Altamira Therapeutics, Inc.

Samuel Wickline

CSO
Altamira Therapeutics, Inc.
Nina Kjellson, General Partner, Canaan

Nina Kjellson

General Partner
Canaan
Brett Monia, CEO, Ionis Pharmaceuticals

Brett Monia

CEO
Ionis Pharmaceuticals
Nagy Habib, Founder and Head of R&D, MiNA Therapeutics

Nagy Habib

Founder & Head of R&D
MiNA Therapeutics
Lori Panther, VP, Clinical Development, Infectious Disease, Moderna, Inc.

Lori Panther

VP, Clinical Development, Infectious Disease
Moderna, Inc.
Robert Mabry, CSO, Orna Therapeutics

Robert Mabry

CSO
Orna Therapeutics
John Androsavich, Global Head, RNA Medicine Lead - Emerging Science & Innovation, Pfizer

John Androsavich

Global Head, RNA Medicine Lead - Emerging Science & Innovation
Pfizer
Aimee Jackson, CSO, Atalanta Therapeutics

Aimee Jackson

CSO
Atalanta Therapeutics
Branden Ryu,CEO,Biorchestra

Branden Ryu

CEO
Biorchestra
Kirk Brown, CNS Program Lead, Alnylam Pharmaceuticals

Kirk Brown

CNS Program Lead
Alnylam Pharmaceuticals
Lori Panther, VP, Clinical Development, Infectious Disease, Moderna Therapeutics

Lori Panther

VP, Clinical Development, Infectious Disease
Moderna Therapeutics
Denis Smit, Commercial Director, Micropore Technologies

Denis Smit

Commercial Director
Micropore Technologies
Heikki Lanckriet, CEOCSO, 4basebio

Heikki Lanckriet

CEO & CSO
4basebio
David Slack CEO, Cend Therapeutics

David Slack

CEO
Cend Therapeutics
Dmitry Samarsky, Chief Technology Officer, Sirnaomics

Dmitry Samarsky

CTO
Sirnaomics
Dave Madge, Vice President, WuXi AppTec

Dave Madge

Vice President
WuXi AppTec
Martin Kögler, Scientist, Chemical Research and Manufacturing Sciences, Axolabs GmbH

Martin Kögler

Scientist, Chemical Research and Manufacturing Sciences
Axolabs
Francois Vigneault, President and CEO, Shape Therapeutics

Francois Vigneault

President and CEO
Shape Therapeutics

DOWNLOAD BROCHURE